NCT00037219View on ClinicalTrials.gov

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2001

Study Completion Date

November 30, 2002

Conditions
Candidiasis
Interventions
DRUG

Anidulafungin, VER002

Trial Locations (1)

19406

Versicor, Inc., King of Prussia

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Vicuron Pharmaceuticals
All Listed Sponsors
collaborator

Vicuron Pharmaceuticals

INDUSTRY

lead

Pfizer

INDUSTRY